Expert Interview
A second look: Discussing the current standard of care and the potential of VLA15, a multivalent recombinant protein vaccine candidate that targets six serotypes of Borrelia currently in development by Valneva and Pfizer.
Ticker(s): VALN, PFEInstitution: UC Davis
- An infectious diseases specialist caring for adult patients with a wide range of complex infections including HIV and TB.
- Assistant Professor in the Division of Infectious Diseases, Department of Medicine at UC Davis. He sees patients at UC Davis Medical Center, and has a laboratory at UC Davis where he uses genetics and biochemistry to study the pathogenesis of M. tuberculosis.
- Research focuses on understanding the immune response to Mycobacterium tuberculosis, the bacteria that causes the human disease tuberculosis, using cutting-edge genetic and proteomic tools.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
